Songling Xuemaikang Capsules for Cerebral Small Vessel Disease

Exclusion Criteria

• •1. Patients with acute ischemic stroke or acute intracranial hemorrhage (e.g., epidural hematoma, subdural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, etc.) or a history of cerebral infarction (non-lacunar) or intracranial hemorrhage within the past 3 months;
• •2. Symptomatic stenosis of the middle cerebral artery and/or internal carotid artery (stenosis rate ≥50%), or asymptomatic stenosis of the middle cerebral artery and/or internal carotid artery (stenosis rate ≥70%);
• •3. Untreated cerebrovascular malformations or intracranial aneurysms (diameter \>3 mm);
• •4. Significant non-vascular white matter lesions (e.g., multiple sclerosis, adult-onset leukoencephalopathy, metabolic encephalopathy, etc.);
• •5. Patients with a history of cognitive impairment due to other causes (e.g., normal pressure hydrocephalus, Alzheimer's disease, Parkinson's disease, multiple sclerosis, encephalitis, etc.);
• •6. A history of intracranial or intramedullary surgery within the past year;
• •7. Severe hepatic, renal, or cardiac insufficiency (ALT or AST \>2 times the upper limit of normal, or serum creatinine \>1.5 times the upper limit of normal, or New York Heart Association \[NYHA\] functional class III or IV);
• •8. Severe three-vessel coronary artery disease as shown by coronary computed tomography angiography or coronary angiography within 90 days or suffering from frequent angina;
• •9. Refractory hyperglycemia uncontrolled by medication (fasting blood glucose \>10 mmol/L, or HbA1c \>8.0%);
• •10. Patients with severe diseases such as cancer and a life expectancy of less than 2 years;
• •11. Patients with psychiatric disorders that affect study medication administration and evaluation;
• •12. Previous allergy or intolerance to Songling Xuemaikang Capsules;
• •13. Contraindications to MRI examination (e.g., claustrophobia, presence of an implantable pacemaker, etc.);
• •14. Patients unable to comply with follow-up examinations or other study procedures due to residential location or other reasons;
• •15. Participation in other clinical trial projects.